Compare AbbVie Inc (ABBV) vs United States Copper Index Fund (CPER) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs United States Copper Index Fund — how do they compare? AbbVie Inc trades at $253.62 (market cap $449.91B), while United States Copper Index Fund trades at $37.02. The key difference: AbbVie Inc pays a 2.72% dividend while United States Copper Index Fund pays none, and AbbVie Inc is trading nearer its 52-week high, United States Copper Index Fund nearer its low. Which is the better fit depends on your goals.
| ABBV | CPER | |
|---|---|---|
Market Cap | $449.91B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $261.07 | $40.60 |
52-Week Low | $184.85 | $27.21 |
Enterprise Value | $513.38B | — |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).
Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.
CPER, the United States Copper Index Fund ETF, trades at $37.84, up 1.47% today. The technical outlook is mixed, with a bullish moving average signal but neutral overall momentum. Recent news highlights strong copper demand from AI and electric vehicles, though supply constraints and price volatility are key themes. Financial ratios are not applicable as this is a commodity ETF tracking copper futures.
The outlook for CPER is tied to copper's structural bull market, driven by AI and green energy demand. Risks include global manufacturing weakness and commodity price swings. Investor sentiment is positive due to copper's supply-demand imbalance, but the ETF's performance remains sensitive to macroeconomic factors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About United States Copper Index Fund
CPER is a commodity ETF that tracks the price of copper futures via the SummerHaven Copper Index. It provides direct exposure to the 'red metal' using a rules-based strategy to select futures contracts, making it a key tool for hedging or betting on industrial growth and electrification.
Read more on CPER →
